Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TUMORLYMPHAINHIBIT

Financiado

Cerrado

Identification characterization and mechanisms of action of new tumor associate...

Identification characterization and mechanisms of action of new tumor associated lymphangiogenesis inhibitors Cancer and tumor metastasis is the largest single cause of death in both, men and women, claiming over 7 million lives each year worldwide and, it is expected that by 2020 the number of dead cancer patients will grow to 10 million... ver más

31/03/2016

ULIEGE

170K€

Presupuesto del proyecto: 170K€

Líder del proyecto

UNIVERSITE DE LIEGE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-03-31 No tenemos la información de la convocatoria

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ULIEGE

0.00€ | Lider

Proyectos interesantes

RTC-2016-4611-1

Medical Technol...

Pharmaceuticals

2K€ Cerrado

ENSAYOS DE DESARROLLO DE FASE CLÍNICA DEL COM...

Medical Technol...

Pharmaceuticals

2M€ Cerrado

PLEC2022-009298

Medical Technol...

Pharmaceuticals

373K€ Cerrado

EVALUACIÓN DEL COMPUESTO ANTITUMORAL DE ORÍGE...

Medical Technol...

Cancer Research

2M€ Cerrado

Cluster-Buster

Medical Technol...

Biotechnology

150K€ Cerrado

SAF2012-36575

Medical Technol...

Cancer Research

193K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

UNIVERSITE DE LIEGE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 170K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer and tumor metastasis is the largest single cause of death in both, men and women, claiming over 7 million lives each year worldwide and, it is expected that by 2020 the number of dead cancer patients will grow to 10 million per year. Metastatic tumor cells utilize blood and lymphatic vessels as routes for dissemination and it is well known that lymphatic vasculature serves as a major route for tumor metastasis. Besides, lymphangiogenesis, the new lymphatic vessels formation from pre-existing ones, is pivotal for cancer cells spreading from primary sites to lymph nodes and, further, to distant tissues. Consequently, the search and identification of new tumor-induced lymphangiogenesis inhibitors and the understanding of their mechanisms of action, are a hot topic in the field of pharmacological research. In the present project, the applicant will finished the characterization of two marine compounds, toluquinol and AD0157, started during a short stay in the host institute. Preliminary results have shown that both compounds have excellent antilymphangiogenic properties in in vitro and ex vivo assays and, in the course of the present project they will be tested in in vivo models and their molecular targets will be revealed. Furthermore, other two new marine compounds will be analyzed in in vitro, ex vivo and in vivo experimental approaches. In these studies the applicant will focus in the behavior of the lymphatic endothelial tip and stalk cells, in order to shed light on their morphological and biochemical features. Hence, this project will increase significantly the acquisition of innovative knowledge on lymphangiogenesis phenomenon, on the different lymphatic endothelial tip/stalk cells features and on the cellular and molecular mechanisms of action of some natural compounds to inhibit tumor-related lymphangiogenesis. Those compounds with excellent antilymphangiogenic properties will be patented in order to be commercially exploitable as antitumor drugs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores